3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Lung Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Non-small-cell Lung Cancer With Somatic EGFR Mutations
2
Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thrombocytosis
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
NSCLC Harboring NRG1 Fusion
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Meningeal Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
pembrolizumab
51
Ipilimumab
50
Cyclophosphamide
43
Nivolumab
41
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
spartalizumab
10
Radiotherapy
10
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
cobimetinib
9
binimetinib
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
Afatinib
×
Clear all
NCT06897735
2026-06-03
EDDIS-a1
Petrov, Andrey
Phase 1
Terminated
4 enrolled